Fludrocortisone in CFS with neurally mediated hypotension
Rowe PC et al. · 2001 · JAMA
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Double-blind trial of fludrocortisone titrated to 0.1 mg/day or placebo for nine weeks.
Dose, route and schedule
Double-blind trial of fludrocortisone titrated to 0.1 mg/day or placebo for nine weeks.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Global wellness response | 7/50 (14%) with fludrocortisone versus 5/50 (10%) with placebo; the difference was inconclusive (p=0.76). |
This comparison studied a specific orthostatic phenotype. It does not answer whether fludrocortisone is effective in a separately diagnosed condition.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- This comparison studied a specific orthostatic phenotype. It does not answer whether fludrocortisone is effective in a separately diagnosed condition.
Source access
Double-blind trial of fludrocortisone titrated to 0.1 mg/day or placebo for nine weeks.
Source reviewed 2026-11-12.
Citation and original source
Original source: Rowe PC et al.. Fludrocortisone in CFS with neurally mediated hypotension JAMA 2001.
Molekul research summary: https://molekul.io/research/fludrocortisone-rowe-2001. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry